<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00328094</url>
  </required_header>
  <id_info>
    <org_study_id>2005P-000299</org_study_id>
    <nct_id>NCT00328094</nct_id>
  </id_info>
  <brief_title>Glycemic Control to Prevent Cardiac Morbidity in Vascular Surgery</brief_title>
  <official_title>Impact of Tight Control of Perioperative Blood Glucose in Patients Undergoing Vascular Surgery on Their Perioperative Cardiovascular and Overall Morbidity and Mortality</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beth Israel Deaconess Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beth Israel Deaconess Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Aggressive intraoperative and postoperative management of blood glucose may substantially
      decrease perioperative cardiovascular and infectious complications in diabetic and
      non-diabetic patients undergoing vascular surgery.

      The purpose of this study is to compare the tight versus traditional blood glucose control in
      diabetics and non-diabetics undergoing vascular surgery in regard to their postoperative
      fatal and nonfatal cardiac outcomes, and the secondary effects such as rate of infections,
      overall morbidity and 30-day mortality.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, prospective controlled trial in both diabetic and non diabetic patients
      undergoing vascular surgery such as abdominal aortic, infra inguinal vascular bypass
      procedures and amputations, comparing tight versus standard blood glucose control regimens in
      the operating room, post anesthesia care unit and in the postoperative vascular intensive
      care unit up to 48 hours and its impact on the cardiovascular, infectious and other morbidity
      and mortality during the hospital admission and up to 30 days from surgery.

      After obtaining informed consent, the study subjects will be randomized to tight versus
      standard blood glucose control regimens. These regimens will be started in the operating room
      and continued for the first 48 hours or until their discharge, whichever is earlier. All the
      patients will be inpatients. Day surgery patients will be excluded.

      The anesthesiologist providing patient care will be given either the tight glucose control
      protocol or the standard sliding scale insulin protocol. In the tight control regimen, target
      blood glucose is 100-150 mg/dl. If 3 consecutive blood glucose (BG) level &gt;150 mg/dL or 1 BG
      level &gt;200 mg/dL, then the insulin infusion will be initiated in the tight control group. The
      insulin infusion rate adjustments will be made based on the blood sugar results. In post
      anesthetic care unit (PACU) and vascular intensive care unit (VICU), these protocols will be
      nurse driven. The adjustments will be made based on the current blood sugar levels as well as
      the insulin infusion rates. They are adjusted in such a way to account for the rate of change
      of blood sugars and the presence of steroid therapy in the patients. The frequency of blood
      glucose testing in this group will be every 1-hour until stable (when frequent changes in
      insulin dosage are no longer necessary, and glucose is in the range of 100 to 150 for 3
      consecutive blood sugar checks); then test every 2 hours for 3 consecutive target values and
      then every 4 hours thereafter. If there is a change in the infusion rates, then blood sugar
      checks will be done every hour and the cycle followed thereafter.

      In the standard sliding scale insulin group, blood sugars will be treated with insulin
      boluses if the blood sugars go more than 150 mg/dL and blood glucose will be monitored every
      4 hours.

      These regimens will be initiated after 2 weeks of in-service training for anesthesiologists,
      post anesthetic care unit (PACU) and vascular intensive care unit (VICU) nurses. The study
      investigators will provide this training. Insulin infusion in the tight control regimen will
      be started through pump piggyback to maintenance intravenous infusion as follows. Insulin
      infusion bags will be made by the pharmacy (100 units in a 100 ml bag). The anesthesiologists
      in the operating room and PACU, and VICU nurses will perform blood glucose monitoring, bolus
      insulin administration, and infusion initiation and rate adjustments as specified by the
      protocol. Blood glucose levels will be tested by finger stick method or arterial line drop
      sample.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    The recruitment rate slowed considerably
  </why_stopped>
  <start_date>March 2006</start_date>
  <completion_date type="Actual">May 2009</completion_date>
  <primary_completion_date type="Actual">April 2008</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Composite (Myocardial Infarction and CHF)</measure>
    <time_frame>hospital length of stay</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of Wound Infections</measure>
    <time_frame>postoperative</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">242</enrollment>
  <condition>Peripheral Vascular Disease</condition>
  <condition>Abdominal Aortic Aneurysm</condition>
  <arm_group>
    <arm_group_label>CII, Continuous Insulin Infusion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Continuous intravenous insulin infusion to control glucose to &lt;150 mg/dL in patients undergoing open peripheral vascular bypass surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IIB, Intermittent insulin boluses</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intermittent intravenous insulin insulin boluses to a blood glucose target of &lt;150mg/dL in patients undergoing peripheral vascular bypass surgery</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>continuous intravenous insulin infusion</intervention_name>
    <description>Tight glucose control versus standard of care</description>
    <arm_group_label>CII, Continuous Insulin Infusion</arm_group_label>
    <arm_group_label>IIB, Intermittent insulin boluses</arm_group_label>
    <other_name>CII-continuous insulin infusion</other_name>
    <other_name>II-Intermittent insulin boluses</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Abdominal aortic surgery

          -  Supra and infrainguinal peripheral vascular bypass surgery

          -  Below knee amputations

          -  Above knee amputations

          -  Diabetics and nondiabetics

          -  American Society of Anesthesiologists (ASA) I-III

        Exclusion Criteria:

          -  Brittle diabetics

          -  ASA 1V,V

          -  Second surgery in same admission
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Balachundhar Subramaniam</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beth Israel Deaconess Medical Center, Boston, MA</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Furnary AP, Zerr KJ, Grunkemeier GL, Starr A. Continuous intravenous insulin infusion reduces the incidence of deep sternal wound infection in diabetic patients after cardiac surgical procedures. Ann Thorac Surg. 1999 Feb;67(2):352-60; discussion 360-2.</citation>
    <PMID>10197653</PMID>
  </reference>
  <reference>
    <citation>van den Berghe G, Wouters P, Weekers F, Verwaest C, Bruyninckx F, Schetz M, Vlasselaers D, Ferdinande P, Lauwers P, Bouillon R. Intensive insulin therapy in critically ill patients. N Engl J Med. 2001 Nov 8;345(19):1359-67.</citation>
    <PMID>11794168</PMID>
  </reference>
  <reference>
    <citation>Zimmerman CR, Mlynarek ME, Jordan JA, Rajda CA, Horst HM. An insulin infusion protocol in critically ill cardiothoracic surgery patients. Ann Pharmacother. 2004 Jul-Aug;38(7-8):1123-9. Epub 2004 May 18.</citation>
    <PMID>15150382</PMID>
  </reference>
  <reference>
    <citation>Kersten JR, Warltier DC, Pagel PS. Aggressive control of intraoperative blood glucose concentration: a shifting paradigm? Anesthesiology. 2005 Oct;103(4):677-8.</citation>
    <PMID>16192757</PMID>
  </reference>
  <verification_date>April 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 18, 2006</study_first_submitted>
  <study_first_submitted_qc>May 18, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 19, 2006</study_first_posted>
  <results_first_submitted>February 28, 2013</results_first_submitted>
  <results_first_submitted_qc>February 28, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 9, 2013</results_first_posted>
  <last_update_submitted>April 10, 2013</last_update_submitted>
  <last_update_submitted_qc>April 10, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 17, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Beth Israel Deaconess Medical Center</investigator_affiliation>
    <investigator_full_name>Balachundhar Subramaniam</investigator_full_name>
    <investigator_title>Staff Anesthesiologist</investigator_title>
  </responsible_party>
  <keyword>Tight</keyword>
  <keyword>Glycemic</keyword>
  <keyword>control</keyword>
  <keyword>outcomes</keyword>
  <keyword>peripheral vascular disease</keyword>
  <keyword>infection</keyword>
  <keyword>cardiovascular</keyword>
  <keyword>morbidity</keyword>
  <keyword>mortality</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aneurysm</mesh_term>
    <mesh_term>Aortic Aneurysm</mesh_term>
    <mesh_term>Vascular Diseases</mesh_term>
    <mesh_term>Aortic Aneurysm, Abdominal</mesh_term>
    <mesh_term>Peripheral Vascular Diseases</mesh_term>
    <mesh_term>Peripheral Arterial Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Perioperative period in Beth Israel Deaconess Medical Center, West Campus was the only location for the recruitment.</recruitment_details>
      <pre_assignment_details>252 were assessed for eligibility. 10 did not meet inclusion criterion.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Continuous Insulin Infusion</title>
          <description>Tight glucose group with insulin infusion</description>
        </group>
        <group group_id="P2">
          <title>Intermittent Insulin Bolus</title>
          <description>Intermittent insulin boluses group</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="117"/>
                <participants group_id="P2" count="125"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="114">2 did not receive intervention. 1 patient refusal</participants>
                <participants group_id="P2" count="122">3 did not receive interevention. 1 post induction arrest. 1 case cancelled.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>assessed for eligibility 252. 10 were found ineligible. 242 were randomized.6 patients did not receive interventions they were supposed to. Total number of patients analyzed were 236.</population>
      <group_list>
        <group group_id="B1">
          <title>Continuous Insulin Infusion</title>
          <description>Tight glucose group with insulin infusion</description>
        </group>
        <group group_id="B2">
          <title>Intermittent Insulin Bolus</title>
          <description>Intermittent insulin boluses group</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="114"/>
            <count group_id="B2" value="122"/>
            <count group_id="B3" value="236"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49"/>
                    <measurement group_id="B2" value="43"/>
                    <measurement group_id="B3" value="92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65"/>
                    <measurement group_id="B2" value="79"/>
                    <measurement group_id="B3" value="144"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67" spread="10"/>
                    <measurement group_id="B2" value="71" spread="11"/>
                    <measurement group_id="B3" value="69" spread="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47"/>
                    <measurement group_id="B2" value="56"/>
                    <measurement group_id="B3" value="103"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67"/>
                    <measurement group_id="B2" value="66"/>
                    <measurement group_id="B3" value="133"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="114"/>
                    <measurement group_id="B2" value="122"/>
                    <measurement group_id="B3" value="236"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Wound Infections</title>
        <time_frame>postoperative</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Continuous Insulin Infusion</title>
            <description>Tight glucose group with insulin infusion</description>
          </group>
          <group group_id="O2">
            <title>Intermittent Insulin Bolus</title>
            <description>Intermittent insulin boluses group</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Wound Infections</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="114"/>
                <count group_id="O2" value="122"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35"/>
                    <measurement group_id="O2" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.23</p_value>
            <method>Chi-squared</method>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>1.29</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.85</ci_lower_limit>
            <ci_upper_limit>1.97</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Composite (Myocardial Infarction and CHF)</title>
        <time_frame>hospital length of stay</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Continuous Insulin Infusion</title>
            <description>Tight glucose group with insulin infusion</description>
          </group>
          <group group_id="O2">
            <title>Intermittent Insulin Bolus</title>
            <description>Intermittent insulin boluses group</description>
          </group>
        </group_list>
        <measure>
          <title>Composite (Myocardial Infarction and CHF)</title>
          <units>Number of patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="114"/>
                <count group_id="O2" value="122"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Study period. Hospital stay</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Continuous Insulin Infusion</title>
          <description>Tight glucose group with insulin infusion</description>
        </group>
        <group group_id="E2">
          <title>Intermittent Insulin Bolus</title>
          <description>Intermittent insulin boluses group</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="114"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="122"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>HYPOGLYCEMIA</sub_title>
                <description>Blood glucose &lt; 60 mg/dL atleast once</description>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="114"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="122"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="114"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="122"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Creatinine &gt; 25% increase</sub_title>
                <description>INcrease in creatinine &gt; 25% in the postoperative period from the preoperative period</description>
                <counts group_id="E1" events="23" subjects_affected="23" subjects_at_risk="114"/>
                <counts group_id="E2" events="22" subjects_affected="22" subjects_at_risk="122"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>A trial to adequately address mortality would require 5000 to 6000 patients. The alpha levels for significance were not adjusted for the interim analyses because of the unplanned issues with subject recruitement as surgery became percutaneous.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Balachundhar Subramaniam, MD MPH</name_or_title>
      <organization>Beth Israel Deaconess Medical Center, Boston, MA</organization>
      <phone>6177542675</phone>
      <email>bsubrama@bidmc.harvard.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

